Patents by Inventor Nicolas BERY

Nicolas BERY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMAERIC PROTEINS AND THERAPEUTIC AGENTS
    Publication number: 20250270519
    Abstract: Provided is a chimaeric protein comprising a ubiquitin ligase domain and a RAS-specific endogenous targeting portion. The ubiquitin ligase domain may be a VHL E3 ligase domain, or a fragment or variant thereof having ubiquitin ligase activity; or a UBOX domain of CHIP, or a fragment or variant thereof having ubiquitin ligase activity. The RAS-specific endogenous targeting portion may be a RAS-specific DARPin; or a RAS-specific intracellular antibody. In particular, the RAS-specific endogenous targeting portion may be a KRAS-specific endogenous targeting portion (for example a KRAS-specific DARPin, or a KRAS-specific intracellular antibody). The chimaeric proteins may be used in the prevention and/or treatment of a RAS-associated disorder, such as a RAS-associated cancer or a RASopathy. Further provided is a chimaeric protein comprising a ubiquitin ligase domain and an LMO2-specific endogenous targeting portion.
    Type: Application
    Filed: May 12, 2021
    Publication date: August 28, 2025
    Inventors: Terrence RABBITTS, Nicolas BERY
  • LMO2 PROTEIN INHIBITORS
    Publication number: 20230303544
    Abstract: The present invention relates to compounds of Formula (I) that function as LMO2 activity: Formula (I) wherein R1, X1, X2, X3, Q, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which LMO2 activity is implicated.
    Type: Application
    Filed: August 18, 2021
    Publication date: September 28, 2023
    Inventors: Terence Rabbits, Nicolas Bery, Carole Bataille, Angela Russell
  • ANTI-RHO GTPASE CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF
    Publication number: 20220213221
    Abstract: Active forms of specific anti Rho GTPase conformational single domain antibodies are useful in the therapeutic and diagnostic fields. In particular, single domain antibodies wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) are defined in Table B.
    Type: Application
    Filed: March 22, 2022
    Publication date: July 7, 2022
    Inventors: Aurelien OLICHON, Laura KELLER, Gilles FAVRE, Nicolas BERY, Patrick CHINESTRA
  • Anti-rho GTPase conformational single domain antibodies and uses thereof
    Patent number: 11319381
    Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: May 3, 2022
    Assignees: INSERM (Institut National de la Santéet de la Recherche Médicale), UniversitéPaul Sabatier Toulouse III, Institut Claudius Regaud
    Inventors: Aurelien Olichon, Laura Keller, Gilles Favre, Nicolas Bery, Patrick Chinestra
  • ANTI-RHO GTPASE CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF
    Publication number: 20210171658
    Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
    Type: Application
    Filed: December 4, 2019
    Publication date: June 10, 2021
    Inventors: Aurelien OLICHON, Laura KELLER, Gilles FAVRE, Nicolas BERY, Patrick CHINESTRA
  • Anti-Rho GTPase conformational single domain antibodies and uses thereof
    Patent number: 10544210
    Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: January 28, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paul Sabatier, Institut Claudius Regaud
    Inventors: Aurelien Olichon, Laura Keller, Gilles Favre, Nicolas Bery, Patrick Chinestra
  • ANTI-RHO GTPASE CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF
    Publication number: 20180022794
    Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
    Type: Application
    Filed: February 2, 2016
    Publication date: January 25, 2018
    Inventors: Aurelien OLICHON, Laura KELLER, Gilles FAVRE, Nicolas BERY, Patrick CHINESTRA